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 GENERAL PART 1.
 
1.1. New Psychoactive Substances (NPS) 
The use of mind-expanding substances is as old as humanity itself. Already 
thousands of years ago, human beings described the use of substances to talk to 
their deities during religious ceremonies.1 Over the years, some well-known 
preparations were passed from generation to generation such as the brewery called 
“Ayahuasca”, which is still used today by indigenous people as traditional spiritual 
medicine in religious ceremonies.1,2 However, in the mid of the twentieth century, 
some widespread psychedelic or entactogenic substances gained more and more 
importance also for common civilization. Prominent and well-known examples for 
these trends are substances or preparations such as cocaine, heroin, lysergic acid 
diethylamide (LSD), cannabis, and amphetamine or its analogs methamphetamine 
and 3,4-methylenedioxy-N-methyl-amphetamine (MDMA), better known as “Ecstasy”. 
Some of them were initially developed for medical use, but never were marketed or 
were taken from market after few years due to their adverse effects, especially 
addictive properties. These substances and preparations were also scheduled over 
the years and the trade became illegal. Over the time, a small number of slightly 
chemically modified analogs appeared on the drugs of abuse market to circumvent 
the existing laws.3-8 However, at the beginning of the nineties, the book “PiHKAL: A 
Chemical Love Story” written by Alexander and Ann Shulgin and its availability via 
internet changed the situation on the drugs of abuse market and triggered the up-
coming of a higher number of chemical related substances.9 As chemist and 
pharmacologist, Alexander Shulgin synthesized a lot of compounds with widespread 
structure variability and administered them to himself.9 The synthesis as well as the 
experiences and effects of the compounds were written down by Shulgin and his wife 
in their books “PiHKAL” and “TiHKAL” and served as references for many drug 
producers and consumers in the world.9,10 Following these experiences and chemical 
structures, the phenomenon of the so-called NPS occurred in the end of the 2000s 
and lasts until today.3-5 Based on known chemical substances and/or known drugs of 
abuse, a high number of new substances appeared on the market to circumvent the 
existing laws and they were sold usually by specialized shops in the internet as 
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“research chemicals”, “legal highs”, “plant food”, “spice”, or “bath salts” marked with 
“not for human consumption”.3-5 However, these substances did not undergo any 
clinical safety studies such as toxicokinetic, toxicodynamic, or toxicological studies.3-5 
Therefore, over the years, a lot of fatal or non-fatal poisonings were described in the 
literature with compounds from different structural classes.3-5 Up-to-date, detection 
and identification of all new substances are one of the main challenges concerning 
the phenomenon of NPS for toxicological analyses.5 Therefore, various drug 
monitoring systems and cooperations e.g. the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA), the United Nation Organization on Drugs and Crime 
(UNODC), and the Swedish STRIDA project were founded to detect and to register 
up-coming NPS.3,4,11,12 The annual reports of the EMCDDA and UNODC together 
with early warning systems help clinicians and laboratories to keep up-to-date.3,4 
According to the 2018 report of the EMCDDA, 670 NPS were identified in Europe 
from 2005 to end of 2017 with annually raising number.4 The most frequently 
reported groups included synthetic cannabinoids, synthetic cathinones, 
phenethylamines, synthetic benzodiazepines, synthetic tryptamines, synthetic 
opioids, and piperazines.3,4 However, according to the European Drug Report 2018, 
the number of new detected compounds declined since 2015.4 This was most 
probably caused by better controlling, better preventing, or by new blanket bans or 
analogue-based legislation in several countries.13,14 For example, such a law was 
introduced 2016 in Germany.13,14 It defined several core structures for 
phenethylamines and synthetic cannabinoids with defined and common 
substituents.13,14 Although the number of newly detected compounds declined, the 
challenges regarding the phenomenon NPS will attend the clinicians and laboratories 
also for the next few years. 
 
1.2. Phenethylamine-Derived NPS 
Among NPS, phenethylamine-derived substances play a central role.4 A well-known 
group of phenethylamines is the so-called 2C-series, which emerged already in the 
early 2000s and were well described in the literature concerning pharmacology, 
metabolism, and misuse.9,15-17 In their book “PiHKAL: A Chemical Love Story”, 
Alexander and Ann Shulgin already described synthesis, effects, and suggested 
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dosage of some 2Cs.9 Following these reports, compounds such as 4-bromo-2,5-
dimethoxy-phenethylamine (2C-B), 4-chloro-2,5-dimethoxy-phenethylamine (2C-C), 
and 4-iodo-2,5-dimethoxy-phenethylamine (2C-I) were reported more and more in 
clinical or forensic toxicology.15 The 2Cs were described as noradrenaline receptor 
agonists as well as serotonin receptor subtype 2A (5-HT2A) agonists, which is also 
one target of LSD and linked to hallucinogenic effects.15 Common dosages range 
from 6 to 150 mg depending on the compound and the administration route.9,15 They 
were shown to be mainly metabolized by O-demethylation or oxidative deamination 
by monoamine oxidases.15,18 Over the years, the most up-coming 2Cs were 
scheduled and new alternatives were synthesized by illicit drug producers.15 
A new potent phenethylamine-based series appeared on the illicit drug market at the 
beginning of the 2010s.3,4,16,17,19-22 The so-called NBOMes represented highly potent 
derivatives of the known 2Cs.16,17,21,23 The substitution of the primary amine group of 
the 2C backbone with an N-2-methoxybenzyl (NBOMe) moiety increased the affinity 
to the 5-HT2A receptors significantly.
23-26 They were originally synthesized as 
radiotracer for positron emission tomography due to their high affinity to the 5-HT2A 
receptors. “[11C]Cimbi-5”, the carbon-11 labeled derivative of 2-(4-iodo-2,5-
dimethoxy)-N-(2-methoxybenzyl)-phenethylamine (25I-NBOMe) was found to be a 
promising tool for investigation of 5-HT2A agonist binding in the living human 
brain.26,27 The first authentic case after self-reported use of 25I-NBOMe, the NBOMe 
derivative of 2C-I, was published in 2013.20 Thereafter, various other NBOMes 
appeared on the drug market such as 2-(4-bromo-2,5-dimethoxy)-N-(2-
methoxybenzyl)-phenethylamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxy)-N-(2-
methoxybenzyl)-phenethylamine (25C-NBOMe), derivatives of 2C-B and 2C-C, 
respectively, and in the meantime, several fatal and non-fatal poisonings were 
reported.16,17,21,26 Due to the significantly increased potency of the NBOMes 
compared to the corresponding 2Cs, poisonings are likely to happen.16,17 Poisonings 
could be based on unknown intake of those compounds or due to wrong declaration 
e.g. as 2C or LSD.16,17,28 Due to the high potency of the NBOMes, very low dosages, 
comparable to those of LSD in the µg ranges are consumed.16,17 They are commonly 
administered sublingually on blotter paper, insufflated, or as nose sprays and sold 
under several street names such as “N-bombs”, “Smiles”, “Cimbi”, “25B”, 25C”, or 
“25I”.16,17,21 They were suggested to lead to effects similar to LSD such as 
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hallucinations, euphoria, powerful visual and sensory effects, unusual body 
sensations, mystical experiences, empathic feelings, and alterations in 
consciousness.17,21,22 The most often reported adverse effects of consumers coming 
to the clinic were agitation, tachycardia, hypertension, and seizures.16,17,21 
Furthermore, NBOMe intake is hard to detect due to the low dosages and presented 
a new challenge to analytical methods.16,17 After few years, the most common 
NBOMes such as 25B-, 25C-, and 25I-NBOMe were scheduled in most countries.16,17 
In 2014, a new class of NBOMes was detected in a seizure from China by German 
custom authorities.29 In contrast to the 2C-derived NBOMes with mescaline-like 
structures, these new detected NBOMes had an amphetamine backbone, with 
several substitutions at the aromatic ring system and/or the nitrogen.29 The detected 
compounds were NBOMe derivatives of amphetamines such as 3,4-dimethoxy-
amphetamine (3,4-DMA), 4-ethyl-amphetamine (4-EA), and 4-methyl-N-methyl-
amphetamine (4-MMA).29 However, no information about their pharmacological 
properties or potential effects were published yet.29 
 
1.3.  In vivo and In vitro Metabolism Studies 
One important analytical challenge in clinical and forensic toxicology is the detection 
and identification of potentially administered or ingested substances or preparations. 
The hype of NPS demanded a lot of new challenges for analytical methods.5-8 
Besides low to ultra-low consumed dosages, the huge structure variability is one of 
the main issues. Analytical methods need to be sensitive and flexible enough to 
ensure the reliable and fast detection and identification of NPS to support clinical 
treatment or to elucidate the cause of fatalities. Usually, information about 
pharmacological and toxicological properties of up-coming NPS is missing because 
they were never tested or investigated in any studies prior to marketing.5 
Furthermore, nothing is known about the toxicity or the route of excretion. The only 
information about effects is often provided by non-scientific trip reports in online drug 
forums. To ensure that an intake of an NPS could be detected and identified in 
clinical or forensic toxicology, several studies need to be performed. Most screening 
procedures covering NPS were based on the detection in urine, which is the matrix of 
choice due to higher concentrations, longer detectability, and easier access and 
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collection compared to e.g. blood samples.5 However, it is often unknown whether 
the NPS is excreted into urine unchanged or even only in form of metabolites.5 
Therefore, metabolism studies are necessary to elucidate the best analytical target in 
urine. Unfortunately, human authentic material is not available in most cases. 
Therefore, metabolism studies must be performed in vivo with mammalian models or 
in vitro to elucidate the metabolism of NPS. Standard study procedures described in 
the literature were based on the application of high dosages to capture as much 
metabolites as possible because it could never be excluded that e.g. a minor rat 
metabolite could be the major biotransformation product in humans.5,30-33 This 
information could be useful to update the analytical methods to ensure that an intake 
of the ingested NPS could be possible in routine toxicological analyses. However, 
animal testing should be restricted due to ethical reasons and species differences 
concerning metabolism or excretion routes should be considered. Therefore, human 
in vitro models could be additionally used to confirm the metabolites found in the 
animal model or to detect different metabolite formation. There are several models to 
elucidate the human in vitro metabolism, namely pooled human liver microsomes 
(pHLM), pooled human liver cytosol (pHLC), or pooled human liver S9 fraction 
(pS9).34-40 Furthermore, alternative models gained more and more importance in the 
last few years such as incubations with primary hepatocytes or with various cell 
lines.35-37 The decision, which model should be used, depends on the aims of the 
respective study. In vitro studies with pHLM or pS9 are well-known, much cheaper, 
and easier to handle than incubations with cell lines or primary hepatocytes.35 On the 
other hand, the more complex an in vitro model is, the more similar to in vivo are the 
results.35 In the most cases, incubations with pHLM or pS9 are sufficient to identify 
the expected main human metabolites and to confirm the metabolites identified in the 
animal model.35 This data could be used to update the routine toxicology screening 
procedures to identify the investigated compounds. 
 
1.4. Cytochrome P450 (CYP) Enzyme Involvement and Kinetics 
The cytochrome P450 (CYP) system is one of the main actors in the metabolism of 
xenobiotics in mammalian.41-45 They are mainly expressed in the liver but also in the 
lung and the intestinal. They belong to the family of oxidoreductases and are 
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organized in various subfamilies.41-45 CYPs are responsible for metabolism of 
endogenous but also for exogenous compounds.41-45 Usually, CYPs make 
xenobiotics more hydrophilic mainly by oxidation or also by reduction prior to 
conjugation to ensure that the metabolites are not reabsorbed and thus excreted 
from the body. In most cases, these metabolic steps lead to detoxification of the 
compound but in rare cases also toxification could be observed. One prominent 
example for this is the biotransformation of paracetamol, which is metabolized to 
toxic metabolites in overdose patients. Furthermore, CYP enzymes could be 
subjected to genetic polymorphism or could be even inhibited or induced by other 
therapeutic drugs or NPS resulting in possible interactions.41-43 Genetic 
polymorphisms could lead to poor metabolizers or ultra-rapid metabolizers resulting 
in varied excretion profiles of the affected compound. Furthermore, interactions 
between NPS and therapeutic drugs could influence both, the excretion route of the 
NPS or of the therapeutic drug leading to possible overdosing or poisoning. It is 
therefore also important to know for NPS, which CYP enzymes are responsible and 
involved in their metabolism. If only one CYP enzyme is involved, kinetic variations 
due to polymorphism or interactions are most likely to occur. Besides CYPs, also 
flavin-containing monooxygenases (FMOs) represents an important system for 
metabolism.44 
After the initial monooxygenases activity screening, the kinetic properties of each 
involved isozyme were determined. The kinetic parameters such as the Michaelis-
Menten constant Km or Vmax are helpful tools to elucidate whether the NPS is a 
relevant substrate for the respective CYP enzyme or not.46-50 The Km and Vmax values 
can be determined using two different approaches.46,47 On the one hand, the 
formation of a specific metabolite catalyzed by one CYP isozyme can be 
measured.46,49 The used enzyme concentration and incubation time have to be in the 
linear range of metabolite formation to get valid results. On the other hand, the 
depletion of the parent compound can be measured.46,49 Depletion rates at defined 
enzyme concentrations are calculated over a defined time range and plotted versus 
substrate concentration to determine the kinetic constants.46 Based on these kinetic 
data, further predictions could be given for the expected human in vivo metabolism 
using the so-called relative activity factor (RAF) approach.44,51,52 Using this approach, 
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a prediction of the contribution of each involved CYP isozyme to the hepatic net 
clearance could be done.44,51,52 
 
1.5. (Nano)Liquid Chromatography-High Resolution Mass 
Spectrometry 
Liquid chromatography (LC)-MS is one of the most important tools in analytical 
toxicology, besides GC-MS, because it is robust and reliable.53-58 Many different 
approaches for the identification of metabolites in various matrices were described in 
the last years based on low or high resolution (HR) MS techniques.53-58 HRMS allows 
the calculation of empirical molecular formulas of precursor masses as well as of the 
fragment ions and thus it is a helpful tool for metabolite identification and also for 
structure elucidation.53-58 Mainly time of flight (TOF) or Orbitrap (OT) mass analyzers 
are used.53-58 Recently, Helfer et al. developed an OT-based LC-HRMS screening 
method for routine drug testing.59,60 This established approach was used as starting 
point to develop specific methods for the identification of metabolites of the studied 
NBOMes. Besides conventional LC methods, nanoLC coupled to HRMS was 
described in the past as useful tool for protein analyses but also described as 
applicable for metabolite identification of small molecules.61-63 
 
1.6. Urine Screening Approaches 
As already mentioned above, the phenomenon of NPS represents one of the main 
challenges concerning analytical toxicology in biosamples.5-7 The occurrence of new 
chemical structures with slight modifications and the usually more potent compounds 
with resulting lower consumed dosages need to be addressed by sophisticated 
bioanalytical methods. However, some approaches for detection and identification of 
NPS in biosamples such as blood plasma or serum, urine, hairs, or even other 
matrices were published in the last years.5-8 In general, the biosamples for 
detectability studies play a central role. For blood analyses, the parent compounds 
usually were suitable targets but with narrow detection window and lower 
concentrations compared to e.g. urine.64 As already mentioned above, urine is the 
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sample of choice for screening methods. Based on metabolism studies, the 
metabolite-based reference libraries could be updated to perform comprehensive 
urine screenings.64 Furthermore, the detection of metabolites in addition to the parent 
compound (if excreted) increases the reliability of results and confirms a suggested 
intake of a NPS. Therefore, comprehensive and broad phase I and phase II 
metabolite identification should be performed. In the present work, the detectability 
studies of the investigated compounds were performed in rat urine after application of 
a dose estimated based on reports of consumer in NPS forums or suggested 
dosages of internet shops in addition to data from scientific publications. Also human 
urine was investigated if available from case work. 
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 AIMS AND SCOPES 2.
The presented work aimed to investigate the metabolic fate of 25B-, 25C-, and 25I-
NBOMe (upper part in Fig. 1), commonly consumed representatives of N-2-
methoxybenzyl substituted potent hallucinogenic NPS and of 3,4-DMA-, 4-EA-, and 
4-MMA-NBOMe (lower part in Fig .1), representatives of a newly discovered group of 
NBOMes. In addition, their detectability in standard urine screening approaches after 
commonly consumed low dosages was elucidated. The studies were performed in rat 
and human urine as well as in human liver preparations using hyphenated MS 
techniques. The extensive metabolized compounds should be furthermore analyzed 
by nanoLC-HRMS/MS to elucidate its power for metabolism studies. For all 
investigated compounds, the kinetic properties of CYP-mediated metabolism were 
determined using substrate depletion approach. 
 
 
Fig. 1: Chemical structures of the studied NBOMes65 
 
The following steps had to be conducted: 
· Detection and identification of the phase I and II metabolites of 25B-, 25C-, 
25I-, 3,4-DMA-, 4-EA-, and 4-MMA-NBOMe in rat urine after high dose 
administration by LC-HRMS/MS or nanoLC-HRMS/MS 
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· Detection, identification, and confirmation of the phase I and II metabolites of 
25B- and 25I-NBOMe in human urine after unknown dosage by LC-HRMS/MS 
· Detection, identification, and confirmation of the phase I and II metabolites in 
human liver preparations 
· Investigations on the power of nanoLC-HRMS/MS for the detection and 
identification of metabolites exemplified for 3,4-DMA- and 4-MMA-NBOMe 
· Investigations of the general monooxygenases involvement in the metabolism 
of NBOMes 
· In vitro CYP kinetic studies using the substrate depletion approach and 
determination of the in vivo contribution to the hepatic net clearance 
· Toxicological detectability in rat urine after low dose administration (and 
human urine for 25B- and 25I-NBOMe after unknown dosage) using standard 
urine screening approaches (SUSAs) by GC-MS, LC-MSn, and  
LC-HRMS/MS31,59,60,66-68 
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 PUBLICATIONS OF THE RESULTS 3.
 
The results of the studies were published in the following publications: 
 
3.1. Studies on the metabolism and toxicological detection of 
the new psychoactive designer drug 2-(4-iodo-2,5- 
Dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine 
(25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, 
and LC-HR-MS/MS69 
(DOI: 10.1007/s00216-015-8828-6) 
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3.2. Metabolic fate and detectability of the new psychoactive 
substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
Methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-
chloro-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human 
and rat urine by GC-MS, LC-MSn, and LC-HR-MS/MS 
approaches70 
(DOI: 10.1016/j.jpba.2016.11.040) 
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3.3. LC-high resolution-MS/MS for identification of 69 
metabolites of the new psychoactive substance 1-(4-
ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-
amine (4-EA-NBOMe) in rat urine and human liver S9 
incubates and comparison of its screening power with 
further MS techniques71 
(DOI: 10.1007/s00216-017-0526-0) 
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3.4. Nano liquid chromatography-high-resolution mass 
spectrometry for the identification of metabolites of the 
two new psychoactive substances N-(ortho-
methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-
methoxybenzyl)-4-methylmethamphetamine72 
(DOI: 10.1016/j.talanta.2018.05.064) 
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3.5. Human cytochrome P450 kinetic studies on six N-2-
methoxybenzyl (NBOMe)-derived new psychoactive 
substances using the substrate depletion approach65 
(DOI: 10.1016/j.toxlet.2017.12.017) 
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 DISCUSSION AND CONCLUSIONS 4.
In the presented work, the metabolic fate in rats and humans of three common 
phenethylamine-derived NPS (25B-, 25C-, and 25I-NBOMe) and three amphetamine-
derived NPS (3,4-DMA-, 4-EA-, and 4-MMA-NBOMe) of the NBOMe group was 
studied. Furthermore, their toxicological detectability in standard urine screening 
procedures was investigated. All compounds showed extensive metabolism in rats 
and humans. LC-HRMS/MS or nanoLC-HRMS/MS allowed the detection and 
tentative identification of numerous of phase I and II metabolites based on their 
HRMS/MS spectra. The fragmentation patterns were characteristic and comparable 
for all investigated NBOMes and also their metabolites. Based on their MS 
fragmentation pattern, the molecules could be broken down in several parts, the so-
called 2C part for 25B-, 25C-, and 25I-NBOMe and their metabolites, the 
amphetamine part for 3,4-DMA-, 4-EA-, and 4-MMA-NBOMe and their metabolites as 
well as the characteristic NBOMe part representative for all studied compounds. 
Except for the N-demethoxybenzyl metabolites, the most abundant fragment ions 
were always formed by the NBOMe part and allowed confident identification together 
with the accurate masses of the protonated precursor molecules and the calculated 
molecular formulas. Furthermore, the fragment ion of m/z 121.0653 (C8H9O
+) coming 
from the NBOMe part represented a group indicating fragment ion for all NBOMe 
compounds and also for their main metabolites with metabolically unmodified 
NBOMe part.73 In addition, the presented work described for the first time an 
observed rearrangement reaction discovered for the 2C-NBOMes based on the 
HRMS/MS fragmentation patterns. 
The used nanoLC approach was applied for the detection and identification of 
metabolites of two amphetamine-derived NBOMes. Furthermore, the results 
concerning detectability were compared to those obtained by conventional LC. The 
suggested higher sensitivity of the nanoLC system could not be proven. However, it 
showed no disadvantages when compared to conventional LC systems with much 
lower eluent consumption and allowed the identification of numerous phase I and II 
metabolites of 3,4-DMA-NBOMe and 4-MMA-NBOMe. 
Following the (nano)LCHRMS/MS data, several metabolic pathways could be 
predicted for the studied compounds. For 25B-, 25C-, and 25I-NBOMe, O-
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demethylation could be proposed to be the main metabolic reaction in rats and 
humans degrading all three methoxy groups, even up to tris-demethylation. 
Furthermore, various aromatic hydroxylations, dehydration, and N-
demethoxybenzylation could be found for the “classic” 2C-NBOMes. N-
demethoxybenzylation lead to the respective well-known 2C compounds (2C-B, 2C-
C, and 2C-I), which were further metabolized by O-demethylation, aromatic 
hydroxylation, and oxidative deamination what was in-line with published 2C 
studies.15,32,33,74 Based on the main metabolic pathways, a lot of combinations could 
also be found leading to high number of identified phase I metabolites (35, 36, and 
37). For 3,4-DMA-NBOMe, an amphetamine-derived NPS, also O-demethylation 
represented the main metabolic reaction together with aromatic hydroxylation. This 
was in-line with published metabolism data for 3,4-DMA.75 In contrast, 4-EA- and 4-
MMA-NBOMe were mainly metabolized by oxidation of the ethyl or methyl rest to the 
corresponding carboxylic acids. Also O-demethylation of the NBOMe part, aliphatic 
and aromatic hydroxylations as well as N-demethoxybenzylation could be observed. 
For 4-MMA-NBOMe, N-demethylation could additionally be found as one of the 
predominant pathways. 
Concerning phase II metabolism, almost all common conjugation steps could be 
observed. The predominant phase II pathways were conjugation to glucuronic acid 
and/or sulfuric acid. For the 2C-NBOMes, also O-methylation and glutathione 
conjugation could be found in rats. N-Acetylation after previous N-
demethoxybenzylation leading to the corresponding 2C was also found. Again being 
in-line with published data.15,32,33 Almost all phase I metabolites of the amphetamine-
derived NBOMes were excreted as conjugates with glucuronic acid and/or sulfuric 
acid. N-Acetylation after previous N-demethoxybenzylation could be observed for 
3,4-DMA- and 4-EA-NBOMe in rats. In addition, for one of the main rat metabolites of 
4-EA-NBOMe, even glycine conjugation could be found after previous oxidation of 
the ethyl side chain to a benzoic acid derivative. 
With regards to the used metabolic models, no relevant species differences could be 
observed. Most phase I and II steps found in rat urine (or human urine if available) 
could be confirmed with the human in vitro tools. Differences in the detected number 
of metabolites could be explained by concentration issues and the collection time of 
rat urine of 24 hours. Nevertheless, for 4-EA-NBOMe, an important limitation of the 
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rat model could also be observed. Oxidation of the ethyl side chain to a benzoic acid 
derivative was found to be the main excretion product in rat urine, but could not be 
detected in the human in vitro model. This was in-line with published data about the 
different metabolism in rats and humans of ethyl benzene to benzoic acid describing 
that the loss of a C-atom was only observed in rats.76-78 Furthermore, N-acetylation, 
O-methylation, as well as glutathione and glycine conjugation could only be detected 
in rat urine most probably due to concentration issues. For the 2C-NBOMes, pHLM 
were used to confirm in vitro phase I metabolites. However, for 25B- and 25I-NBOMe 
human urine was available to confirm the phase II metabolites. Again, no relevant 
species differences could be observed concerning metabolic pathways or metabolic 
patterns. For further studies on the human in vitro metabolism of amphetamine-
derived NBOMes, incubations with pS9 instead of pHLM were performed, which was 
developed by Richter et al. and found to deliver better results and covered the 
formation of both, phase I and II metabolites.34,35 
In addition to the identification of metabolites in urine and human liver preparations, 
the involvement of the ten most abundant human hepatic CYPs and FMO3 was 
tested. Incubations with recombinantly expressed isozymes revealed the main 
involvement of CYP2C19, CYP2D6, and CYP3A4 for all investigated NBOMes and in 
addition, CYP1A2 for 4-EA-NBOMe and CYP2B6 for 4-MMA-NBOMe. Furthermore, 
for these mainly involved isozymes, the kinetic constants (Km and Vmax values) were 
determined using the substrate depletion approach. The determination allowed the 
assessment of the human in vivo contribution of each CYP isozyme to the hepatic net 
clearance. All NBOMes were found to be good CYP substrates indicated by low Km 
values in the nanomolar range particularly for CYP2C19 and CYP2D6. The 
calculation of the contribution to the hepatic net clearance based on the RAF 
approach suggested a main contribution of CYP2C19 and CYP2D6. Both isozymes 
are known to be subjected to genetic polymorphism resulting in possible 
interindividual variations in the metabolism. However, several CYP isozymes were 
involved and thus drug-drug or drug-food interactions are not likely.  
The detectability studies were performed using rat urine collected over 24-h period 
after administration of an estimated consumer dosage. The established standard 
urine screening procedures using GC-MS, LC-MSn, and LC-HRMS/MS after suitable 
wok-up were applied.31,59,60,66-68 For all NBOMes, the parent compound was not 
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detected in the rat urine samples. In addition to the rat urine samples, human urine 
samples were available and tested for 25B- and 25I-NBOMe. In contrast to the rat 
urine samples, the parent compounds were detectable in the human urine samples. 
This could be explained by potential overdosing or poisoning. Furthermore, the time 
of intake and the consumed dosages were not known. However, the parent 
compounds were not found to be suitable targets for urinalysis. Based on the 
presented data, screening procedures need to include metabolites e.g. after O-
demethylation or oxidation of the side chains. The applied GC-MS approach was not 
able to detect an intake of the studied 2C-NBOMes in the rat urine samples after low 
dose administrations most probably due to sensitivity issues. However, an intake of 
25B- and 25I-NBOMe in the authentic human urine samples and in the rat urine 
samples after high dose administration suggested that in case of acute overdosing or 
poisoning an intake should also be detectable by GC-MS. In contrast, the 
amphetamine-derived NBOMes were detectable also with the GC-MS SUSA via their 
metabolites. Nevertheless, clinical and forensic screening procedures for NBOMes 
should be based on highly sensitive LC-MS devices to ensure reliable detection of 
the described compounds even after low dose or longer time since administration. 
The results presented in this work showed that metabolism studies play a central role 
in analytical toxicology. NBOMe-derived NPS were extensively metabolized and the 
parent compounds were only detectable after assumed high dosages. Therefore, 
metabolism studies should be systematically performed to keep the screening 
methods up to date and to ensure reliable screening procedures. The information 
provided by this work helps to detect an intake of the studied compounds. 
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 SUMMARY 5.
The presented work describes the metabolic fate and detectability of 
phenethylamine-derived new psychoactive substances in rats and humans using 
various hyphenated low and high resolution mass spectrometry. All compounds 
showed extensive metabolism with series of phase I and II metabolites. Main 
metabolic pathways were O-demethylation, aromatic hydroxylation, and N-
demethoxybenzylation for 25B-, 25C-, 25I-, and 3,4-DMA-NBOMe as well as 
oxidation of the side chain to the corresponding carboxylic acids, O-demethylation, 
and hydroxylations for 4-EA- and 4-MMA-NBOMe. The proposed main metabolic 
pathways were comparable in rats and humans. Initial monooxygenases activity 
screenings and CYP kinetic studies using substrate depletion approach revealed that 
CYP2C19 and CYP2D6 were the main human in vivo contributors to the hepatic net 
clearance. All NBOMes were only detectable via their metabolites with established 
standard urine screening approaches by GC-MS, LC-MSn, and LC-HRMS/MS. 
Recommended analytical targets were the O-demethylated metabolites with or 
without conjugation to glucuronic acid for 25B-, 25C-, 25I-, and 3,4-DMA-NBOMe and 
the carboxylic acid metabolite with or without additional demethylation for 4-EA-
NBOMe and 4-MMA-NBOMe. Furthermore, a nanoLC-HRMS/MS approach was 
developed for the metabolism studies of 3,4-DMA- and 4-MMA-NBOMe and its power 
was elucidated for metabolite detection and identification. 
 

REFERENCES 
 
27 
 REFERENCES 6.
1. Gaujac A, Navickiene S, Collins MI, Brandt SD, de Andrade JB. Analytical 
techniques for the determination of tryptamines and beta-carbolines in plant 
matrices and in psychoactive beverages consumed during religious 
ceremonies and neo-shamanic urban practices. Drug Test Anal. 2012;4(7-
8):636-648. 
2. Meyer MR, Caspar A, Brandt SD, Maurer HH. A qualitative/quantitative 
approach for the detection of 37 tryptamine-derived designer drugs, 5 beta-
carbolines, ibogaine, and yohimbine in human urine and plasma using 
standard urine screening and multi-analyte approaches. Anal Bioanal Chem. 
2014;406(1):225-237. 
3. UNODC. World Drug Report. In: UNODC, ed: United Nations publication; 
2017. https://www.unodc.org/wdr2017/index.html. 
4. EMCDDA. European Drug Report 2018. Publications of of the European 
Union. 2018. 
http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT
18001ENN_PDF.pdf. 
5. Welter-Luedeke J, Maurer HH. New Psychoactive Substances: Chemistry, 
Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives 
With Modified Ring Systems. Ther Drug Monit. 2016;38(1):4-11. 
6. Favretto D, Pascali JP, Tagliaro F. New challenges and innovation in forensic 
toxicology: focus on the "New Psychoactive Substances". J Chromatogr A. 
2013;1287:84-95. 
7. Peters FT. Recent developments in urinalysis of metabolites of new 
psychoactive substances using LC-MS. Bioanalysis. 2014;6(15):2083-2107. 
REFERENCES 
 
28 
8. Wagmann L, Maurer HH. Bioanalytical Methods for New Psychoactive 
Substances. Handb Exp Pharmacol. 2018. 
9. Shulgin A. Pihkal, A Chemical Love Story. Transform Press, Berkley (CA). 
1991. 
10. Shulgin A, Shulgin A. Tihkal: The Continuation. Transform Press, Berkley 
(CA). 1997. 
11. Beck O, Backberg M, Signell P, Helander A. Intoxications in the STRIDA 
project involving a panorama of psychostimulant pyrovalerone derivatives, 
MDPV copycats. Clin Toxicol (Phila). 2018;56(4):256-263. 
12. Backberg M, Jonsson KH, Beck O, Helander A. Investigation of drug products 
received for analysis in the Swedish STRIDA project on new psychoactive 
substances. Drug Test Anal. 2018;10(2):340-349. 
13. EMCDDA. Germany - Country Drug Report 2017. In: Publications Office of the 
European Union; 2017. 
http://www.emcdda.europa.eu/system/files/publications/4528/TD0416906ENN.
pdf 
14. Bundestag. Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver 
Stoffe. Bundesgesetzblatt. 2016;55. 
15. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: 
phenethylamine designer drug review. J Med Toxicol. 2013;9(2):172-178. 
16. Suzuki J, Dekker MA, Valenti ES, et al. Toxicities associated with NBOMe 
ingestion-a novel class of potent hallucinogens: a review of the literature. 
Psychosomatics. 2015;56(2):129-139. 
17. Kyriakou C, Marinelli E, Frati P, et al. NBOMe: new potent hallucinogens--
pharmacology, analytical methods, toxicities, fatalities: a review. Eur Rev Med 
Pharmacol Sci. 2015;19(17):3270-3281. 
REFERENCES 
 
29 
18. Meyer MR, Maurer HH. Metabolism of designer drugs of abuse: an updated 
review. Curr Drug Metab. 2010;11(5):468-482. 
19. Zuba D, Sekula K. Analytical characterization of three hallucinogenic N-(2-
methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug 
Test Anal. 2013;5(8):634-645. 
20. Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new 
potent 5-HT2A agonist designer drug. Clin Toxicol (Phila). 2013;51(3):174-
177. 
21. Lawn W, Barratt M, Williams M, Horne A, Winstock A. The NBOMe 
hallucinogenic drug series: Patterns of use, characteristics of users and self-
reported effects in a large international sample. J Psychopharmacol. 
2014;28(8):780-788. 
22. Ninnemann A, Stuart GL. The NBOMe series: a novel, dangerous group of 
hallucinogenic drugs. J Stud Alcohol Drugs. 2013;74(6):977-978. 
23. Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-
iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head 
twitch response. Neuropharmacology. 2014;77:200-207. 
24. Hansen M, Phonekeo K, Paine JS, et al. Synthesis and structure-activity 
relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS 
Chem Neurosci. 2014;5(3):243-249. 
25. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of 
serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with 
superpotent N-benzyl phenethylamine agonists. Mol Pharmacol. 
2006;70(6):1956-1964. 
REFERENCES 
 
30 
26. Ettrup A, Hansen M, Santini MA, et al. Radiosynthesis and in vivo evaluation 
of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET 
tracers. Eur J Nucl Med Mol Imaging. 2011;38(4):681-693. 
27. Ettrup A, Palner M, Gillings N, et al. Radiosynthesis and evaluation of 11C-
CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med. 
2010;51(11):1763-1770. 
28. Suzuki J, Poklis JL, Poklis A. "My friend said it was good LSD": a suicide 
attempt following analytically confirmed 25I-NBOMe ingestion. J Psychoactive 
Drugs. 2014;46(5):379-382. 
29. Westphal F, Girreser U, Waldmuller D. Analytical characterization of four new 
ortho-methoxybenzylated amphetamine-type designer drugs. Drug Test Anal. 
2016;8(9):910-919. 
30. Welter J, Kavanagh P, Meyer MR, Maurer HH. Benzofuran analogues of 
amphetamine and methamphetamine: studies on the metabolism and 
toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-
MS and LC-(HR)-MS(n) techniques. Anal Bioanal Chem. 2015;407(5):1371-
1388. 
31. Welter J, Meyer MR, Wolf EU, Weinmann W, Kavanagh P, Maurer HH. 2-
methiopropamine, a thiophene analogue of methamphetamine: studies on its 
metabolism and detectability in the rat and human using GC-MS and LC-(HR)-
MS techniques. Anal Bioanal Chem. 2013;405(10):3125-3135. 
32. Theobald DS, Fritschi G, Maurer HH. Studies on the toxicological detection of 
the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat 
urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci. 2007;846(1-2):374-377. 
REFERENCES 
 
31 
33. Theobald DS, Putz M, Schneider E, Maurer HH. New designer drug 4-iodo-
2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and 
toxicological detection in rat urine using gas chromatographic/mass 
spectrometric and capillary electrophoretic/mass spectrometric techniques. J 
Mass Spectrom. 2006;41(7):872-886. 
34. Richter LHJ, Maurer HH, Meyer MR. New psychoactive substances: Studies 
on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-alpha-
PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in 
comparison to primary human hepatocytes, and human urine. Toxicol Lett. 
2017;280:142-150. 
35. Richter LHJ, Flockerzi V, Maurer HH, Meyer MR. Pooled human liver 
preparations, HepaRG, or HepG2 cell lines for metabolism studies of new 
psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, 
MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal. 
2017;143:32-42. 
36. Richter LH, Kaminski YR, Noor F, Meyer MR, Maurer HH. Metabolic fate of 
desomorphine elucidated using rat urine, pooled human liver preparations, 
and human hepatocyte cultures as well as its detectability using standard urine 
screening approaches. Anal Bioanal Chem. 2016;408(23):6283-6294. 
37. Wohlfarth A, Roman M, Andersson M, et al. 25C-NBOMe and 25I-NBOMe 
metabolite studies in human hepatocytes, in vivo mouse and human urine with 
high-resolution mass spectrometry. Drug Test Anal. 2017;9(5):680-698. 
38. Franz F, Angerer V, Brandt SD, et al. In vitro metabolism of the synthetic 
cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation 
of their thermal stability. Drug Test Anal. 2017;9(2):311-316. 
REFERENCES 
 
32 
39. Boumrah Y, Humbert L, Phanithavong M, Khimeche K, Dahmani A, Allorge D. 
In vitro characterization of potential CYP- and UGT-derived metabolites of the 
psychoactive drug 25B-NBOMe using LC-high resolution MS. Drug Test Anal. 
2016;8(2):248-256. 
40. Caspar AT, Gaab JB, Michely JA, Brandt SD, Meyer MR, Maurer HH. 
Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-
Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability 
in urine studied by GC-MS, LC-MS(n) , and LC-HR-MS/MS. Drug Test Anal. 
2018;10(1):184-195. 
41. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: 
structure/function, genetic polymorphisms and role in drug metabolism. 
Pharmacol Ther. 2005;106(3):357-387. 
42. Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Curr Drug 
Metab. 2005;6(3):259-274. 
43. Springer D, Staack R, Paul L, Kraemer T, Maurer H. Identification of 
cytochrome P450 enzymes involved in the metabolism of 3 ',4 '-
methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in 
human liver microsomes. Xenobiotica. 2005;35(3):227-237. 
44. Wagmann L, Meyer MR, Maurer HH. What is the contribution of human FMO3 
in the N-oxygenation of selected therapeutic drugs and drugs of abuse? 
Toxicol Lett. 2016;258:55-70. 
45. Zollner A, Buchheit D, Meyer MR, Maurer HH, Peters FT, Bureik M. 
Production of human phase 1 and 2 metabolites by whole-cell 
biotransformation with recombinant microbes. Bioanalysis. 2010;2(7):1277-
1290. 
REFERENCES 
 
33 
46. Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for 
cytochrome P450-mediated biotransformation reactions using a substrate 
depletion approach. Drug Metabolism and Disposition. 2002;30(7):831-837. 
47. Youdim K, Dodia R. Comparison between recombinant P450s and human liver 
microsomes in the determination of cytochrome P450 Michaelis-Menten 
constants. Xenobiotica. 2010;40(4):235-244. 
48. Nath A, Atkins WM. A theoretical validation of the substrate depletion 
approach to determining kinetic parameters. Drug Metab Dispos. 
2006;34(9):1433-1435. 
49. Schwaninger AE, Meyer MR, Zapp J, Maurer HH. Sulfation of the 3,4-
methylenedioxymethamphetamine (MDMA) metabolites 3,4-
dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-
methoxymethamphetamine (HMMA) and their capability to inhibit human 
sulfotransferases. Toxicol Lett. 2011;202(2):120-128. 
50. Masimirembwa CM, Otter C, Berg M, et al. Heterologous expression and 
kinetic characterization of human cytochromes P-450: validation of a 
pharmaceutical tool for drug metabolism research. Drug Metab Dispos. 
1999;27(10):1117-1122. 
51. Crespi CL, Miller VP. The use of heterologously expressed drug metabolizing 
enzymes--state of the art and prospects for the future. Pharmacol Ther. 
1999;84(2):121-131. 
52. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Application of the relative 
activity factor approach in scaling from heterologously expressed cytochromes 
p450 to human liver microsomes: studies on amitriptyline as a model 
substrate. J Pharmacol Exp Ther. 2001;297(1):326-337. 
REFERENCES 
 
34 
53. Maurer HH, Meyer MR. High-resolution mass spectrometry in toxicology: 
current status and future perspectives. Arch Toxicol. 2016;90(9):2161-2172. 
54. Meyer MR, Maurer HH. Review: LC coupled to low- and high-resolution mass 
spectrometry for new psychoactive substance screening in biological matrices 
- Where do we stand today? Anal Chim Acta. 2016;927:13-20. 
55. Meyer MR, Helfer AG, Maurer HH. Current position of high-resolution MS for 
drug quantification in clinical & forensic toxicology. Bioanalysis. 
2014;6(17):2275-2284. 
56. Maurer HH. What is the future of (ultra) high performance liquid 
chromatography coupled to low and high resolution mass spectrometry for 
toxicological drug screening? J Chromatogr A. 2013;1292:19-24. 
57. Meyer MR, Maurer HH. Current applications of high-resolution mass 
spectrometry in drug metabolism studies. Anal Bioanal Chem. 
2012;403(5):1221-1231. 
58. Meyer MR, Maurer HH. Current status of hyphenated mass spectrometry in 
studies of the metabolism of drugs of abuse, including doping agents. Anal 
Bioanal Chem. 2012;402(1):195-208. 
59. Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Orbitrap technology 
for comprehensive metabolite-based liquid chromatographic-high resolution-
tandem mass spectrometric urine drug screening - exemplified for 
cardiovascular drugs. Anal Chim Acta. 2015;891:221-233. 
60. Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Liquid 
chromatography-high resolution-tandem mass spectrometry using Orbitrap 
technology for comprehensive screening to detect drugs and their metabolites 
in blood plasma. Anal Chim Acta. 2017;965:83-95. 
REFERENCES 
 
35 
61. Meyer MR, Bergstrand MP, Helander A, Beck O. Identification of main human 
urinary metabolites of the designer nitrobenzodiazepines clonazolam, 
meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution 
mass spectrometry for drug testing purposes. Anal Bioanal Chem. 
2016;408(13):3571-3591. 
62. Wickremsinhe ER, Singh G, Ackermann BL, Gillespie TA, Chaudhary AK. A 
review of nanoelectrospray ionization applications for drug metabolism and 
pharmacokinetics. Curr Drug Metab. 2006;7(8):913-928. 
63. Spaggiari D, Geiser L, Rudaz S. Coupling ultra-high-pressure liquid 
chromatography with mass spectrometry for in-vitro drug-metabolism studies. 
Trac-Trends in Analytical Chemistry. 2014;63:129-139. 
64. Maurer HH. How can analytical diagnostics in clinical toxicology be 
successfully performed today? Ther Drug Monit. 2012;34(5):561-564. 
65. Caspar AT, Meyer MR, Maurer HH. Human cytochrome P450 kinetic studies 
on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances 
using the substrate depletion approach. Toxicol Lett. 2018;285:1-8. 
66. Maurer HH, Pfleger K, Weber AA. Mass spectral data of drugs, poisons, 
pesticides, pollutants and their metabolites. Weinheim: Wiley-VCH; 2016. 
67. Wissenbach DK, Meyer MR, Remane D, Philipp AA, Weber AA, Maurer HH. 
Drugs of abuse screening in urine as part of a metabolite-based LC-MSn 
screening concept. Anal Bioanal Chem. 2011;400(10):3481-3489. 
68. Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH. Development 
of the first metabolite-based LC-MS(n) urine drug screening procedure-
exemplified for antidepressants. Anal Bioanal Chem. 2011;400(1):79-88. 
REFERENCES 
 
36 
69. Caspar AT, Helfer AG, Michely JA, et al. Studies on the metabolism and 
toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in 
human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS. Anal 
Bioanal Chem. 2015;407(22):6697-6719. 
70. Caspar AT, Brandt SD, Stoever AE, Meyer MR, Maurer HH. Metabolic fate 
and detectability of the new psychoactive substances 2-(4-bromo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 
2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine 
(25C-NBOMe) in human and rat urine by GC-MS, LC-MS(n), and LC-HR-
MS/MS approaches. J Pharm Biomed Anal. 2017;134:158-169. 
71. Caspar AT, Westphal F, Meyer MR, Maurer HH. LC-high resolution-MS/MS for 
identification of 69 metabolites of the new psychoactive substance 1-(4-
ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) 
in rat urine and human liver S9 incubates and comparison of its screening 
power with further MS techniques. Anal Bioanal Chem. 2018;410(3):897-912. 
72. Caspar AT, Meyer MR, Westphal F, Weber AA, Maurer HH. Nano liquid 
chromatography-high-resolution mass spectrometry for the identification of 
metabolites of the two new psychoactive substances N- ( ortho -
methoxybenzyl)-3,4-dimethoxyamphetamine and N- ( ortho -methoxybenzyl)-
4-methylmethamphetamine. Talanta. 2018;188:111-123. 
73. Caspar AT, Kollas AB, Maurer HH, Meyer MR. Development of a quantitative 
approach in blood plasma for low-dosed hallucinogens and opioids using LC-
high resolution mass spectrometry. Talanta. 2018;176:635-645. 
REFERENCES 
 
37 
74. Theobald DS, Maurer HH. Identification of monoamine oxidase and 
cytochrome P450 isoenzymes involved in the deamination of phenethylamine-
derived designer drugs (2C-series). Biochem Pharmacol. 2007;73(2):287-297. 
75. Midha KK, Bailey K, Cooper JK, Hubbard JW. Metabolic O-demethylation of 
3,4-dimethoxyamphetamine in vivo in dog and monkey. Xenobiotica. 
1979;9(8):485-490. 
76. Engstrom K, Elovaara E, Aitio A. Metabolism of ethylbenzene in the rat during 
long-term intermittent inhalation exposure. Xenobiotica. 1985;15(4):281-286. 
77. Engstrom K, Riihimaki V, Laine A. Urinary disposition of ethylbenzene and m-
xylene in man following separate and combined exposure. Int Arch Occup 
Environ Health. 1984;54(4):355-363. 
78. Saghir SA, Rick DL, McClymont EL, Zhang F, Bartels MJ, Bus JS. Mechanism 
of ethylbenzene-induced mouse-specific lung tumor: metabolism of 
ethylbenzene by rat, mouse, and human liver and lung microsomes. Toxicol 
Sci. 2009;107(2):352-366. 

ABBREVIATIONS 
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 ABBREVIATIONS 7.
2C-B   4-bromo-2,5-dimethoxy-phenethylamine 
2C-C   4-chloro-2,5-dimethoxy-phenethylamine 
2C-I   4-iodo-2,5-dimethoxy-phenethylamine 
3,4-DMA  3,4-dimethoxy-amphetamine 
4-EA   4-ethyl-amphetamine 
4-MMA  4-methyl-N-methyl-amphetamine 
3,4-DMA-NBOMe N-(2-methoxybenzyl)-3,4-dimethoxyamphetamine 
4-EA-NBOMe N-(2-methoxybenzyl)-4-ethylamphetamine 
4-MMA-NBOMe N-(2-methoxybenzyl)-4-methyl-N-methyl-amphetamine 
5-HT   serotonin 
25B-NBOMe 2-(4-bromo-2,5-dimethoxy)-N-(2-methoxybenzyl)-phenethylamine 
25C-NBOMe 2-(4-chloro-2,5-dimethoxy)-N-(2-methoxybenzyl)-phenethylamine 
25I-NBOMe  2-(4-iodo-2,5-dimethoxy)-N-(2-methoxybenzyl)-phenethylamine 
CYP   human cytochrome P450 
e.g.   exempli gratia, for example 
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction 
FMO   flavin-containing monooxygenases 
GC   gas chromatography 
HR   high resolution 
Km   Michaelis-Menten constant 
LC   liquid chromatography 
LSD   lysergic acid diethylamide 
ABBREVIATIONS 
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MDMA  3,4-methylenedioxy-N-methyl-amphetamine 
MS   mass spectrometry 
MSn   multi stage mass spectrometry 
MS/MS  tandem mass spectrometry 
NBOMe  N-2-methoxybenzyl 
NPS   new psychoactive substance(s) 
OT   Orbitrap 
pHLC   pooled human liver cytosol 
pHLM   pooled human liver microsomes 
pS9   pooled human liver S9 fraction 
RAF   relative activity factor 
SPE   solid-phase extraction 
SUSA   standard urine screening approach 
TOF   time of flight 
UNODC  United Nations Office on Drugs and Crime 
UP   urine precipitation 
Vmax theoretical maximum reaction velocity that would occur at an 
infinite substrate concentration 
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 ZUSAMMENFASSUNG 8.
Die Dissertation beschreibt den Metabolismus und die Nachweisbarkeit von neuen 
psychoaktiven Substanzen des Phenethylamintyps in Ratten und Menschen mittels 
nieder- und hochauflösender Massenspektrometrie. Die Substanzen zeigten einen 
ausgeprägten Metabolismus mit vielen Phase I und II Metaboliten. Die 
Hauptstoffwechselschritte waren O-Demethylierung, aromatische Hydroxylierung und 
N-Demethoxybenzylierung für 25B-, 25C-, 25I- und 3,4-DMA-NBOMe, Oxidation der 
Seitenketten zu den entsprechenden Carbonsäuren sowie O-Demethylierung und 
Hydroxylierung für 4-EA- und 4-MMA-NBOMe. Die Hauptschritte waren in Ratten und 
Menschen vergleichbar. Kinetische Untersuchungen zu den am Metabolismus 
beteiligten CYP Enzymen zeigten, dass CYP2C19 und CYP2D6 hauptsächlich an 
der hepatischen Ausscheidung der Substanzen im Menschen beteiligt sind. Die in 
Urin durchgeführten Untersuchungen zur Nachweisbarkeit zeigten, dass die 
Substanzen nur durch ihre Metaboliten mittels etablierter Urinscreeningverfahren 
nachweisbar waren. Für 25B-, 25C-, 25I-, und 3,4-DMA-NBOMe wurden die 
jeweiligen O-demethylierten Metaboliten mit oder ohne Konjugation an 
Glucuronsäure und die jeweiligen Carbonsäure Metaboliten mit oder ohne 
zusätzliche Demethylierung für 4-EA- und 4-MMA-NBOMe als geeignete analytische 
Marker identifiziert. Des Weiteren wurde die Einsetzbarkeit eines neu entwickelten 
Verfahrens basierend auf nanoLC-HRMS/MS für die Identifizierung von Metaboliten 
getestet.  
